Shockwave Medical (DB:36M) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

36M Stoklara Genel Bakış

A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.

Şirket hakkında

36M temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	3/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 7.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 18.35% oranında artması öngörülüyor

Risk Analizi

Kar marjları (20.7%) geçen yılın (43.2%) altında

Hissedarlar geçen yıl sulandırıldı

Shockwave Medical, Inc. Rakipler

Carl Zeiss Meditec

XTRA:AFX

€5.8b

Siemens Healthineers

XTRA:SHL

€58.5b

Eckert & Ziegler

XTRA:EUZ

€926.4m

Drägerwerk KGaA

XTRA:DRW3

€834.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Shockwave Medical
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$307.70
52 Haftanın En Yüksek Seviyesi	US$307.70
52 Haftanın En Düşük Seviyesi	US$145.45
Beta	0.88
11 Aylık Değişim	0.098%
3 Aylık Değişim	28.69%
1 Yıllık Değişim	18.57%
33 Yıllık Değişim	121.37%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	673.12%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	36M	DE Medical Equipment	DE Pazar
7D	0.4%	-0.6%	1.1%
1Y	18.6%	10.5%	18.9%

Getiri vs. Endüstri: 36M geçen yıl % 8.3 oranında getiri sağlayan German Medical Equipment sektörünü aştı.

Getiri vs Piyasa: 36M geçen yıl % 13.8 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 36M's price volatile compared to industry and market?
36M volatility
36M Average Weekly Movement	4.6%
Medical Equipment Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 36M hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 36M 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	1,468	Doug Godshall	shockwavemedical.com

Shockwave Medical, Inc. Temel Bilgiler Özeti

Shockwave Medical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
36M temel i̇stati̇sti̇kler
Piyasa değeri	€11.58b
Kazançlar(TTM)	€150.70m
Gelir(TTM)	€726.27m

76.9x

F/K Oranı

15.9x

P/S Oranı

36M aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
36M gelir tablosu (TTM)
Gelir	US$787.97m
Gelir Maliyeti	US$102.53m
Brüt Kâr	US$685.44m
Diğer Giderler	US$521.94m
Kazançlar	US$163.50m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

Aug 05, 2024

Hisse başına kazanç (EPS)	4.35
Brüt Marj	86.99%
Net Kâr Marjı	20.75%
Borç/Özkaynak Oranı	97.5%

36M uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

36M Stoklara Genel Bakış

Ödüller

Risk Analizi

Shockwave Medical, Inc. Rakipler

XTRA:AFX

€5.8b

XTRA:SHL

€58.5b

XTRA:EUZ

€926.4m

XTRA:DRW3

€834.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Recent updates

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.48 (vs US$1.07 in 1Q 2023)

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Now 21% undervalued

New minor risk - Shareholder dilution

Independent Director recently sold €14m worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$4.01 (vs US$6.02 in FY 2022)

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Shockwave Medical, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Now 22% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.97 in 3Q 2022)

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

New minor risk - Shareholder dilution

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.79 (vs US$0.71 in 2Q 2022)

Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index

Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board

Key Executive recently sold €548k worth of stock

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

First quarter 2023 earnings released: EPS: US$1.07 (vs US$0.41 in 1Q 2022)

Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023

Investor sentiment improves as stock rises 15%

Independent Director recently sold €132k worth of stock

Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: US$6.02 (vs US$0.26 loss in FY 2021)

ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million.

ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023

ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Now 23% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.97 (vs US$0.055 in 3Q 2021)

ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022

ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease

Independent Director recently sold €192k worth of stock

Chief Accounting Officer recently sold €1.1m worth of stock

ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.71 (vs US$0.012 loss in 2Q 2021)

Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China

Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years

First quarter 2022 earnings released: EPS: US$0.41 (vs US$0.68 loss in 1Q 2021)

ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022